Blazquez-Fernandez A, Navarro-Lopez V, Marcos-Anton S, Cano-de-la-Cuerda R
J Clin Med. 2025; 14(3).
PMID: 39941510
PMC: 11818769.
DOI: 10.3390/jcm14030839.
Blok K, Klein Kranenbarg R, Ananth K, Engelenburg H, van den Bosch A, Giannini L
Eur J Neurol. 2025; 32(2):e70052.
PMID: 39907163
PMC: 11795420.
DOI: 10.1111/ene.70052.
Jatczak-Pawlik I, Jurewicz A, Domowicz M, Ewiak-Paszynska A, Stasiolek M
Cells. 2025; 13(24.
PMID: 39768177
PMC: 11674340.
DOI: 10.3390/cells13242086.
Niedziela N, Nowak-Kiczmer M, Malciene L, Stasiolek M, Niedziela J, Czuba Z
Int J Mol Sci. 2024; 25(19).
PMID: 39408830
PMC: 11476431.
DOI: 10.3390/ijms251910502.
Niedziela N, Nowak-Kiczmer M, Malciene L, Stasiolek M, Zalejska-Fiolka J, Czuba Z
Diagnostics (Basel). 2024; 14(17).
PMID: 39272777
PMC: 11394557.
DOI: 10.3390/diagnostics14171993.
A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis.
Desu H, Sawicka K, Wuerch E, Kitchin V, Quandt J
Front Neurol. 2024; 15:1382468.
PMID: 38654736
PMC: 11035744.
DOI: 10.3389/fneur.2024.1382468.
Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
Arroyo Pereiro P, Munoz-Vendrell A, Leon Moreno I, Bau L, Matas E, Romero-Pinel L
J Neurol. 2023; 271(4):1599-1609.
PMID: 38085343
PMC: 10973070.
DOI: 10.1007/s00415-023-12135-w.
Spatial transcriptomics and neurofilament light chain reveal changes in lesion patterns in murine autoimmune neuroinflammation.
Brummer T, Schillner M, Steffen F, Kneilmann F, Wasser B, Uphaus T
J Neuroinflammation. 2023; 20(1):262.
PMID: 37957728
PMC: 10644497.
DOI: 10.1186/s12974-023-02947-y.
The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?.
Ellen O, Ye S, Nheu D, Dass M, Pagnin M, Ozturk E
Int J Mol Sci. 2023; 24(13).
PMID: 37446290
PMC: 10342336.
DOI: 10.3390/ijms241311112.
Development of an ultrasensitive microfluidic assay for the analysis of Glial fibrillary acidic protein (GFAP) in blood.
Fazeli B, Huss A, de San Jose N, Otto M, Tumani H, Halbgebauer S
Front Mol Biosci. 2023; 10:1175230.
PMID: 37168256
PMC: 10164994.
DOI: 10.3389/fmolb.2023.1175230.
Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.
Maier S, Barcutean L, Andone S, Manu D, Sarmasan E, Bajko Z
Int J Mol Sci. 2023; 24(5).
PMID: 36901807
PMC: 10002756.
DOI: 10.3390/ijms24054375.
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
Barro C, Healy B, Liu Y, Saxena S, Paul A, Polgar-Turcsanyi M
Neurol Neuroimmunol Neuroinflamm. 2022; 10(1).
PMID: 36376097
PMC: 9749933.
DOI: 10.1212/NXI.0000000000200052.
Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.
Floro S, Carandini T, Pietroboni A, De Riz M, Scarpini E, Galimberti D
Neurol Neuroimmunol Neuroinflamm. 2022; 9(4).
PMID: 35534236
PMC: 9128043.
DOI: 10.1212/NXI.0000000000001164.
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.
Biernacki T, Kokas Z, Sandi D, Fuvesi J, Fricska-Nagy Z, Farago P
Int J Mol Sci. 2022; 23(6).
PMID: 35328802
PMC: 8951485.
DOI: 10.3390/ijms23063383.
Linking immune-mediated damage to neurodegeneration in multiple sclerosis: could network-based MRI help?.
Groppa S, Gonzalez-Escamilla G, Eshaghi A, Meuth S, Ciccarelli O
Brain Commun. 2021; 3(4):fcab237.
PMID: 34729480
PMC: 8557667.
DOI: 10.1093/braincomms/fcab237.
Potential Role of CHI3L1+ Astrocytes in Progression in MS.
Cubas-Nunez L, Gil-Perotin S, Castillo-Villalba J, Lopez V, Solis Tarazona L, Gasque-Rubio R
Neurol Neuroimmunol Neuroinflamm. 2021; 8(3).
PMID: 33658322
PMC: 7931642.
DOI: 10.1212/NXI.0000000000000972.
Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
Robinson T, Abdelhak A, Bose T, Meinl E, Otto M, Zettl U
Cells. 2020; 9(12).
PMID: 33255854
PMC: 7761295.
DOI: 10.3390/cells9122543.
Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
Schneider R, Bellenberg B, Gisevius B, Hirschberg S, Sankowski R, Prinz M
Neurol Neuroimmunol Neuroinflamm. 2020; 8(1).
PMID: 33172960
PMC: 7713721.
DOI: 10.1212/NXI.0000000000000906.
Serum Glial Fibrillary Acidic Protein: A Surrogate Marker of the Activity of Multiple Sclerosis.
Sharquie I, Gawwam G, Abdullah S
Medeni Med J. 2020; 35(3):212-218.
PMID: 33110673
PMC: 7584269.
DOI: 10.5222/MMJ.2020.48265.
A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
Huss A, Otto M, Senel M, Ludolph A, Abdelhak A, Tumani H
Front Neurol. 2020; 11:608.
PMID: 32765393
PMC: 7378743.
DOI: 10.3389/fneur.2020.00608.